Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00828867




Registration number
NCT00828867
Ethics application status
Date submitted
8/12/2008
Date registered
22/01/2009
Date last updated
19/06/2017

Titles & IDs
Public title
Single Dose Escalation First Time in Human PK Study
Scientific title
A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects
Secondary ID [1] 0 0
111341
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infections, Bacterial 0 0
Infections, Bacterial 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 100 mg GSK investigational drug
Treatment: Drugs - 200 mg GSK investigational drug
Treatment: Drugs - 400 mg GSK investigational drug
Treatment: Drugs - 800 mg GSK investigational drug
Treatment: Drugs - 2000 mg GSK investigational drug
Treatment: Drugs - 1500 mg GSK investigational drug
Treatment: Drugs - 800mg fed GSK investigational drug
Treatment: Drugs - 3000mg GSK investigational drug
Treatment: Drugs - 4000mg GSK investigational drug
Treatment: Drugs - 100 mg GSK investigational drug
Treatment: Drugs - 200 mg GSK investigational drug
Treatment: Drugs - 400 mg GSK investigational drug
Treatment: Drugs - 800 mg GSK investigational drug
Treatment: Drugs - 2000 mg GSK investigational drug
Treatment: Drugs - 1500 mg GSK investigational drug
Treatment: Drugs - 800mg fed GSK investigational drug
Treatment: Drugs - 3000mg GSK investigational drug
Treatment: Drugs - 4000mg GSK investigational drug

Experimental: Cohort 1 - 100mg

Experimental: Cohort 2 - 200mg

Experimental: Cohort 3 - 400mg

Experimental: Cohort 4 - 800mg

Experimental: Cohort 5 - 1500mg

Experimental: Cohort 6 - 2000mg

Experimental: Cohort 7 - 800mg with food

Experimental: Cohort 8 - 3000mg

Experimental: Cohort 9 - 4000mg

Experimental: Cohort 1 - 100mg

Experimental: Cohort 2 - 200mg

Experimental: Cohort 3 - 400mg

Experimental: Cohort 4 - 800mg

Experimental: Cohort 5 - 1500mg

Experimental: Cohort 6 - 2000mg

Experimental: Cohort 7 - 800mg with food

Experimental: Cohort 8 - 3000mg

Experimental: Cohort 9 - 4000mg


Treatment: Drugs: 100 mg GSK investigational drug


Treatment: Drugs: 200 mg GSK investigational drug


Treatment: Drugs: 400 mg GSK investigational drug


Treatment: Drugs: 800 mg GSK investigational drug


Treatment: Drugs: 2000 mg GSK investigational drug


Treatment: Drugs: 1500 mg GSK investigational drug


Treatment: Drugs: 800mg fed GSK investigational drug


Treatment: Drugs: 3000mg GSK investigational drug


Treatment: Drugs: 4000mg GSK investigational drug


Treatment: Drugs: 100 mg GSK investigational drug


Treatment: Drugs: 200 mg GSK investigational drug


Treatment: Drugs: 400 mg GSK investigational drug


Treatment: Drugs: 800 mg GSK investigational drug


Treatment: Drugs: 2000 mg GSK investigational drug


Treatment: Drugs: 1500 mg GSK investigational drug


Treatment: Drugs: 800mg fed GSK investigational drug


Treatment: Drugs: 3000mg GSK investigational drug


Treatment: Drugs: 4000mg GSK investigational drug


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram intervals, and ECG rhythm.
Timepoint [1] 0 0
Eighteen days
Primary outcome [2] 0 0
Pharmacokinetic parameters following single dose administration: area under the plasma concentration curve AUC 0 to inf, AUC 0 to t, AUC 0 to 24, maximum observed concentration , time to maximum observed concentration , terminal half life .
Timepoint [2] 0 0
Two days, Three days (3000mg and 4000mg only)
Primary outcome [3] 0 0
Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram intervals, and ECG rhythm.
Timepoint [3] 0 0
Eighteen days
Primary outcome [4] 0 0
Pharmacokinetic parameters following single dose administration: area under the plasma concentration curve AUC 0 to inf, AUC 0 to t, AUC 0 to 24, maximum observed concentration , time to maximum observed concentration , terminal half life .
Timepoint [4] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [1] 0 0
AUC 0 to inf and Cmax following single dose administration for the assessment of dose proportionality
Timepoint [1] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [2] 0 0
Amount excreted of unchanged study drug and renal clearance
Timepoint [2] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [3] 0 0
AUC 0 to inf, AUC 0 to t, AUC 0 to 24, Cmax, tmax and tlag if deemed appropriate with and without high fat calorie meal
Timepoint [3] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [4] 0 0
AUC 0 to inf and Cmax following single dose administration for the assessment of dose proportionality
Timepoint [4] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [5] 0 0
Amount excreted of unchanged study drug and renal clearance
Timepoint [5] 0 0
Two days, Three days (3000mg and 4000mg only)
Secondary outcome [6] 0 0
AUC 0 to inf, AUC 0 to t, AUC 0 to 24, Cmax, tmax and tlag if deemed appropriate with and without high fat calorie meal
Timepoint [6] 0 0
Two days, Three days (3000mg and 4000mg only)

Eligibility
Key inclusion criteria
- Healthy

- male

- non-childbearling potential females

- Body weight greater than or equal to 50 kg (110 lbs) for men and greater than or equal
to 45 kg (99 lbs) for women. Body mass index (BMI) between 18.5-29.9 kg/m2 inclusive.

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form

- QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block on Screening
ECG
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that
will be screened for include amphetamines, barbiturates, cocaine, opiates,
cannabinoids and benzodiazepines.

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of screening.

- A positive test for HIV antibody.

- History of regular alcohol consumption within 6 months of the study defined as:

an average weekly intake of greater than 21 units or an average daily intake of greater
than 3 units (males), or defined as an average weekly intake of greater than 14 units or an
average daily intake of greater than 2 units (females). A standard unit is defined as 10g
ethanol which is equivalent to 100mL wine, 250mL full strength beer, 470mL light beer, 30mL
spirits

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the dosing day in the current study:
30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the dosing
day.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
dose of study medication, unless in the opinion of the Investigator and GSK Medical
Monitor the medication will not interfere with the study procedures or compromise
subject safety.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or GSK
Medical Monitor, contraindicates their participation.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Pregnant females as determined by positive [serum or urine] human chorionic
gonadotropin (hCG) test at screening or prior to dosing.

- Lactating females.

- Subjects who have asthma or a history of asthma within the past 6 months.

- History of smoking or history of regular use of tobacco- or nicotine-containing
products within 3 months prior to screening.

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos,
satsuma, ugli, tangerine, and tangelo, exotic citrus fruits, grapefruit hybrids or
fruit juices from 7 days prior to the first dose of study medication

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a first time in human (FTIH) study of single escalating doses of investigational
study drug to investigate safety, tolerability, and pharmacokinetics in healthy subjects
Trial website
https://clinicaltrials.gov/show/NCT00828867
Trial related presentations / publications
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 2013 May;57(5):2005-9. doi: 10.1128/AAC.01779-12. Epub 2013 Feb 12.
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 2013 May;57(5):2005-9. doi: 10.1128/AAC.01779-12. Epub 2013 Feb 12.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications